Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials

The study evaluated the efficacy of ritlecitinib, a dual JAK3/TEC family kinase inhibitor, in 191 patients aged ≥12 years with alopecia areata (AA) and ≥50% scalp hair loss. Patients were categorized into severe AA (SALT score 50-94) and very severe AA (SALT score 95-100). At Month 24, 70.2% of patients with severe AA and 54.8% with very severe AA achieved a SALT score ≤20, indicating significant scalp hair regrowth. Eyebrow and eyelash improvements were also observed, with 60.9% of severe AA and 56.5% of very severe AA patients showing eyebrow improvement, and 70.0% and 45.3% showing eyelash improvement, respectively. The study concludes that ritlecitinib 50 mg daily is effective in promoting hair regrowth in patients with severe and very severe AA. The study was funded by Pfizer Inc.